Metabolic Targets in Nonalcoholic Fatty Liver Disease

nork Esler, William P., Bence, Kendra K.
Argitaratua izan da Cell Mol Gastroenterol Hepatol (2019)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study

nork Bergman, Arthur, Carvajal‐Gonzalez, Santos, Tarabar, Sanela, Saxena, Aditi R., Esler, William P., Amin, Neeta B.
Argitaratua izan da Clin Pharmacol Drug Dev (2020)

Activity-dependent isolation of the presenilin– γ-secretase complex reveals nicastrin and a γ substrate

nork Esler, William P., Kimberly, W. Taylor, Ostaszewski, Beth L., Ye, Wenjuan, Diehl, Thekla S., Selkoe, Dennis J., Wolfe, Michael S.
Argitaratua 2002

Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and De Novo Lipogenesis of EGFRvIII Human Glioblastoma Cells

nork Jones, Jessica E. C., Esler, William P., Patel, Rushi, Lanba, Adhiraj, Vera, Nicholas B., Pfefferkorn, Jeffrey A., Vernochet, Cecile
Argitaratua izan da PLoS One (2017)

Fibrillar β-Amyloid Induces Microglial Phagocytosis, Expression of Inducible Nitric Oxide Synthase, and Loss of a Select Population of Neurons in the Rat CNS In Vivo

nork Weldon, Derik T., Rogers, Scott D., Ghilardi, Joseph R., Finke, Matthew P., Cleary, James P., O’Hare, Eugene, Esler, William P., Maggio, John E., Mantyh, Patrick W.
Argitaratua izan da J Neurosci (1998)

Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems

nork Ross, Trenton T., Crowley, Collin, Kelly, Kenneth L., Rinaldi, Anthony, Beebe, David A., Lech, Matthew P., Martinez, Robert V., Carvajal-Gonzalez, Santos, Boucher, Magalie, Hirenallur-Shanthappa, Dinesh, Morin, Jeffrey, Opsahl, Alan C., Vargas, Sarah R., Bence, Kendra K., Pfefferkorn, Jeffrey A., Esler, William P.
Argitaratua izan da Cell Mol Gastroenterol Hepatol (2020)

Targeting host metabolism by inhibition of acetyl-Coenzyme A carboxylase reduces flavivirus infection in mouse models

nork Jiménez de Oya, Nereida, Esler, William P., Huard, Kim, El-Kattan, Ayman F., Karamanlidis, Georgios, Blázquez, Ana-Belén, Ramos-Ibeas, Priscila, Escribano-Romero, Estela, Louloudes-Lázaro, Andrés, Casas, Josefina, Sobrino, Francisco, Hoehn, Kyle, James, David E., Gutiérrez-Adán, Alfonso, Saiz, Juan-Carlos, Martín-Acebes, Miguel A.
Argitaratua izan da Emerg Microbes Infect (2019)

Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes

nork Griffith, David A., Kung, Daniel W., Esler, William P., Amor, Paul A., Bagley, Scott W., Beysen, Carine, Carvajal-Gonzalez, Santos, Doran, Shawn D., Limberakis, Chris, Mathiowetz, Alan M., McPherson, Kirk, Price, David A., Ravussin, Eric, Sonnenberg, Gabriele E., Southers, James A., Sweet, Laurel J., Turner, Scott M., Vajdos, Felix F.
Argitaratua izan da J Med Chem (2014)

Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946)

nork Scott, William J., Hentemann, Martin F., Rowley, R. Bruce, Bull, Cathy O., Jenkins, Susan, Bullion, Ann M., Johnson, Jeffrey, Redman, Anikó, Robbins, Arthur H., Esler, William, Fracasso, R. Paul, Garrison, Timothy, Hamilton, Mark, Michels, Martin, Wood, Jill E., Wilkie, Dean P., Xiao, Hong, Levy, Joan, Stasik, Enrico, Liu, Ningshu, Schaefer, Martina, Brands, Michael, Lefranc, Julien
Argitaratua izan da ChemMedChem (2016)

Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction

nork Gutierrez, Jemy A., Liu, Wei, Perez, Sylvie, Xing, Gang, Sonnenberg, Gabriele, Kou, Kou, Blatnik, Matt, Allen, Richard, Weng, Yan, Vera, Nicholas B., Chidsey, Kristin, Bergman, Arthur, Somayaji, Veena, Crowley, Collin, Clasquin, Michelle F., Nigam, Anu, Fulham, Melissa A., Erion, Derek M., Ross, Trenton T., Esler, William P., Magee, Thomas V., Pfefferkorn, Jeffrey A., Bence, Kendra K., Birnbaum, Morris J., Tesz, Gregory J.
Argitaratua izan da Mol Metab (2021)